Nootropics for Memory and Focus: Benefits, Risks, and What the Evidence Says

The word nootropic is usually used for substances that are intended to support cognitive functions such as memory, attention, learning, or mental performance. That sounds simple enough. The reality, however, is much more complicated.

Today, the term can describe very different things—from prescription medications to compounds sold as cognitive-enhancement products or dietary supplements. And while the idea of taking something that could make the brain work better is naturally appealing, scientific evidence does not always match the promises surrounding these substances.

That distinction matters, especially in the United States.

What Are Nootropics Supposed to Do?

In the broadest sense, nootropics are associated with attempts to influence functions such as:

• memory and recall;
• attention and concentration;
• learning;
• alertness;
• mental processing;
• resistance to fatigue or cognitive stress.

Some compounds described as nootropics have been proposed to influence neurotransmitter systems, cellular metabolism, blood flow, oxidative processes, or communication between neurons. But substances placed under the same “nootropic” label may work in completely different ways.

This is one reason the word itself can be misleading. Nootropics are not a single, clearly defined therapeutic drug class in U.S. medicine.

The Evidence Is More Complicated Than the Name Suggests

Perhaps the most important point is that a plausible biological mechanism does not automatically mean that a substance produces meaningful improvements in memory, attention, or everyday functioning.

Piracetam is a useful example. It is one of the compounds historically associated with the concept of nootropics, yet evidence supporting its use for cognitive impairment has remained uncertain.

A Cochrane review concluded that the available evidence was not strong enough to support piracetam for dementia or cognitive impairment in clinical practice. A more recent systematic review and meta-analysis published in 2024 again examined its effects on memory in adults with memory impairment, reflecting the continuing uncertainty surrounding its clinical benefits.

This illustrates a larger principle: improvements reported in small studies, laboratory measures, or individual observations do not necessarily translate into reliable clinical benefits.

Why the U.S. Approach Is Different

In the United States, medications generally need convincing evidence of safety and effectiveness for a specific indication before receiving FDA approval.

Several substances commonly discussed online as nootropics do not have FDA approval for cognitive enhancement. Racetam compounds such as piracetam, aniracetam, coluracetam, and phenylpiracetam are not FDA-approved drugs for use in the United States.

Piracetam is particularly important because products containing it have appeared on the U.S. supplement market despite its regulatory status. A study published in JAMA Internal Medicine analyzed products marketed for cognitive enhancement and found piracetam in several of them, sometimes in amounts that differed considerably from what consumers might expect.

So the fact that a product can be purchased online should never be confused with evidence that it is FDA-approved, medically recommended, or proven effective.

Cognitive Problems Require More Than a “Brain Booster”

Memory difficulties and reduced concentration can have many causes. Sleep deprivation, depression, anxiety, medication side effects, substance use, nutritional problems, neurological disease, and other medical conditions can all affect cognition.

That is why treating the underlying cause matters more than simply trying to stimulate cognitive performance.

Even in mild cognitive impairment (MCI), where memory and thinking changes are more noticeable than expected with normal aging, medication is not automatically the answer. An American Academy of Neurology guideline found insufficient evidence to support the routine use of cholinesterase inhibitors for mild cognitive impairment and emphasized discussing the limitations of medication evidence with patients.

The situation is different when a person has a diagnosed neurological disease for which specific medications have demonstrated benefit.

When Cognitive Medications Do Have an Established Role

Certain medications used in U.S. neurology can help cognitive symptoms in particular conditions, but they should not simply be grouped together with products marketed as “smart drugs.”

For example, cholinesterase inhibitors such as donepezil, rivastigmine, and galantamine are used for symptoms of Alzheimer’s disease. Memantine may also be used, particularly in moderate to severe disease.

These medications have defined clinical indications. They are not general-purpose memory enhancers for healthy people.

This difference is essential. A treatment designed for a diagnosed neurological disorder is very different from taking a substance in the hope of becoming more focused, productive, or mentally sharp.

What About Anxiety, Mood, Sleep, and Attention?

Claims surrounding nootropics sometimes extend far beyond memory. Products may be promoted for anxiety, depression, sleep problems, attention difficulties, or even neurological disorders.

Those claims deserve particular caution.

A substance that affects the nervous system can potentially influence mood, sleep, alertness, or anxiety—but that does not make it an established treatment for a psychiatric or neurological condition. The FDA has repeatedly taken action against products marketed with unsupported disease-treatment claims.

For conditions such as ADHD, depression, anxiety disorders, epilepsy, dementia, or sleep disorders, U.S. treatment is based on the specific diagnosis and evidence-supported therapies rather than on the broad label of “nootropics.”

More Brain Activity Is Not Always Better

The desire to improve memory or concentration is understandable. When someone feels mentally exhausted or forgetful, the promise of a pill that makes thinking clearer can be extremely attractive.

But the brain is not simply a machine that performs better when one chemical pathway is increased.

Attention, memory, mood, sleep, and alertness are closely connected. A substance that increases wakefulness may interfere with sleep. Something that feels stimulating may increase anxiety. And a product that appears harmless because it is sold as a supplement may still contain pharmacologically active ingredients.

The real question is therefore not simply, “Does this substance affect the brain?”

The more important questions are: Does it produce a meaningful benefit? Has that benefit been demonstrated in good clinical trials? What are the risks? And is it appropriate for the condition being treated?

Those questions make the discussion around nootropics less dramatic—but much more medically useful.

References

• Petersen RC, Lopez O, Armstrong MJ, et al. Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90(3):126–135. doi:10.1212/WNL.0000000000004826.
  Relevant pages: 126–135.
  Why it matters: Reviews evidence for the assessment and management of mild cognitive impairment and explains the lack of convincing evidence for routine pharmacologic cognitive enhancement in MCI.
• Gouhie FA, Barbosa KO, Cruz ABR, Wellichan MM, Zampolli TM. Cognitive effects of piracetam in adults with memory impairment: A systematic review and meta-analysis. Clinical Neurology and Neurosurgery. 2024;243:108358. doi:10.1016/j.clineuro.2024.108358.
  Pages: The publication uses article number 108358 rather than a traditional page range.
  Why it matters: Evaluates randomized clinical evidence concerning piracetam and memory performance in adults with memory impairment.
• Flicker L, Grimley Evans J. Piracetam for dementia or cognitive impairment. Cochrane Database of Systematic Reviews. 2001;(2). doi:10.1002/14651858.CD001011.
  Pages: Cochrane article number CD001011; no conventional page range.
  Why it matters: Found that available evidence was inadequate to support piracetam as a treatment for dementia or cognitive impairment in clinical practice.
• Cohen PA, Zakharevich I, Gerona R. Presence of Piracetam in Cognitive Enhancement Dietary Supplements. JAMA Internal Medicine. 2020;180(3):458–459. doi:10.1001/jamainternmed.2019.5507.
  Relevant pages: 458–459.
  Why it matters: Laboratory analysis demonstrated the presence of piracetam in products marketed for cognitive enhancement and highlighted concerns about dosage, labeling, and regulatory status in the United States.
• National Institute on Aging. How Is Alzheimer’s Disease Treated?
  Pages: Online medical resource; no page range.
  Why it matters: Summarizes medications used in the United States for cognitive and behavioral symptoms of Alzheimer’s disease, including cholinesterase inhibitors and memantine.
• U.S. Food and Drug Administration. Arizona Company and CEO Sentenced for Illegal Distribution of Tianeptine and Other Drugs and Ordered to Forfeit $2.4 Million. February 5, 2024.
  Pages: Online regulatory publication; no page range.
  Why it matters: Confirms that racetam compounds including piracetam, aniracetam, coluracetam, and phenylpiracetam are not FDA-approved drugs for use in the United States.